Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Drugmakers slash prices to obtain China's bulk-buy contracts: state media

Published 08/20/2020, 09:43 AM
Updated 08/20/2020, 09:45 AM
© Reuters.
AZN
-
PFE
-
BMY
-
SHCAY
-

BEIJING/SHANGHAI (Reuters) - Drugmakers have slashed prices by up to 95% to win state contracts in China's largest bidding round of its drug procurement programme, state media said on Thursday.

Beijing has pushed forward a national scheme where global pharmaceutical giants and domestic copycats have to go through a bidding process and chop prices low enough to elbow out competitors to be eligible to sell their products in bulk at public hospitals.

In the latest bidding round for contracts worth hundreds of billions yuan in total, drugmakers cut prices by 53% on average, state media Xinhua reported, citing preliminary bidding results.

It involves 55 types of medicines, more than the previous two rounds of bidding.

A total of 56 drugs were open for bidding, including some products that contributed more than $1 billion each to foreign drugmakers' sales in 2019 but face challenges from generic versions offered by local drugmakers, including AstraZeneca Plc's (L:AZN) heart disease treatment Brilinta, and blood-thinning blockbuster Eliquis jointly developed by Pfizer Inc (N:PFE) and Bristol Myers Squibb Co (N:BMY).

However, foreign companies quoted high in Thursday's bidding and barely secured any contracts, said ICBC International Research analyst Zhang Jialin.

More expensive brand-name drugs still had opportunities in the market not covered by the national procurement scheme, thanks to their higher awareness among patients and doctors compared with cheaper generic drugs, Zhang said.

Sharp (OTC:SHCAY) price cuts promised by Chinese companies for fear of losing government contracts may not be practical, said Wang Yue, a professor at Peking University's School of Health Humanities.

"When the market changes, like when labour and logistics costs rise, the (low drug) prices are hard to sustain," Wang told Reuters.

Wang said he also worried that the bulk-buy scheme might drive smaller drugmakers to the brink of a loss.

    "The buying group is over centralized and accounts for a major share of the China market," Wang said. "Many companies actually have no power to bargain with the government."

For most products in Thursday's bidding, if only one company wins the bid to supply a certain drug, the winner can bag up to half of the total procurement volume in the first year.

Some 80% of the volume can be shared if a product has at least four bid-winners, the procurement authorities said in an official guideline last month.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.